Is OVID or PBYI more undervalued in 2026?

CirclFi compares Ovid Therapeutics Inc. (OVID) and Puma Biotechnology Inc (PBYI) using 13 institutional-grade valuation models. OVID has a Quality of Company score of 5.3/10 while PBYI scores 8.4/10.

Which is a better buy — OVID or PBYI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OVID and PBYI valuations compare?

OVID at $2.64 and PBYI at $7.24 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OVID vs PBYI Valuation Comparison 2026 — Intrinsic Value Analysis

OVID

Biotechnology

Ovid Therapeutics Inc.

Quality

5.3

out of 10

Value Trap

LOW

Price

$2.64

Last close

Models

9/13

Active

PBYI

Biotechnology

Puma Biotechnology Inc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$7.24

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	OVID Fair Value	OVID Upside	PBYI Fair Value	PBYI Upside
Bayesian DCF	Intrinsic	$0.80	-69.8%	$6.50	-10.2%
Earnings Power Value	Intrinsic	—	—	$4.28	-40.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.83	-68.7%	$4.34	-40.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OVID vs PBYI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OVID vs PBYI — Which Stock Is More Undervalued?

PBYI scores higher with a 8.4/10 quality rating vs OVID's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ovid Therapeutics Inc. (OVID) and Puma Biotechnology Inc (PBYI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OVID currently trades at $2.64 with a QOC of 5.3/10, while PBYI trades at $7.24 with a QOC of 8.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).